Objective To explore the clinical efficacy of Tongxinluo Capsule combined with routine western medicine in the prevention of restenosis after percutaneous coronary intervention（ PCI）. Methods In total 180 patients underwent PCI were randomly divided into a research group and a control group

with 90 cases in each. Both groups were treated with routine western medicine. Placebo capsules were added to the control group

with 3 capsules each time

3 times per day

while Tongxinluo Capsules were given to the research group

with same dosage regimen. Treatment course lasted for 12 months. After operation

monthly follow-ups were given to both groups

and the recurrence of angina and adverse cardio-cerebrovascular events were recorded. Coronary angiography was conducted pre-operation

at 6 to 12 months post-operation or at a chosen time due to patient’s clinical indications. And post-operative restenosis was observed. Results Within 6 months post-operation

effective rate of research group was 81. 1%

whereas control group 67. 8%

which showed research group was better than control group（ χ2= 4. 21

P < 0. 05）. Within 12 months after operation

effective rate of research group was 75. 6%

whereas control group 60. 0%

which indicated research group was better than control group（ χ2= 4. 99

P < 0. 05）. In the 6th month after operation

the degree of coronary artery stenosis

late luminal loss（ LLL） and LLL index were significantly lower in the research group than those in control group

while the net gain of luminal diameter and the net gain index in the research group were significantly higher than those in control group（ P < 0. 01）. It was found within the 12-month follow ups that the recurrence of angina

adverse cardio-cerebrovascular events and myocardial infarction incidence were significantly lower in research group than those in control group（ P < 0. 05）. Conclusion On the basis of routine western medicine

adding Tongxinluo Capsule can significantly reduce the occurrence of restenosis after PCI.